Diagnostic of large vessel aneurysms as applicable to PPPM by Dmitry I Cherepakhin et al.
MEETING ABSTRACT Open Access
Diagnostic of large vessel aneurysms as
applicable to PPPM
Dmitry I Cherepakhin2, Yuri V Belov1, Eduard R Charchyan1, Olga M Bogopolskaya1, Sergey V Suchkov2,3*,
Igor A Yevtyushkin4, Vladlen V Bazylev4
From EPMA-World Congress 2013
Brussels, Belgium. 20-21 September 2013
Verification and confirmation of the diagnosis of cardio-
vascular disease is a very important segment of PPPM.
Among PPPM-related clinical models, aortic aneurisms
(AA) represent a niche illustrating great significance
among cardiovascular diseases. Diagnosis and treatment
of AA patients is appearing to be complicated because
of cryptic clinical manifestations or masking other ill-
nesses. There was a strong demand of finding a method
of diagnostics which allows not only detecting of small
vessel aneurism, but also its’ progressing to large vessel
aneurisms (LVA). We would suggest a multistep proce-
dure to set up novel approaches for diagnosing early AA
development. The assumption is based on molecular
imbalance occurred in the tissue and bloodstream.
Molecular changes are appearing to be important ele-
ment making the diagnosis of LVA. And it’s thus impor-
tant to stress the presence of key elements of the study,
i.e., biopredictors or biomarkers, to create efficient diag-
nostic methods of LVA. The latter would allow diagnos-
ing a multistep process of progressing aneurisms in
record time and may help to reduce the disabling and
mortality rates. Its major molecular biomarkers of LVA’s
monitoring: Osteoprotegerin (OPG) has a high specifi-
city in the AA analysis; it is an early marker for its diag-
nosis. The leading role in the pathogenesis belongs to
metalloproteases (MMP-1, MMP-2), that destroy elastin
in the aortic wall. The shift of balance between factors
of activation and tissue inhibitors of MMPs enchases
degradation of elastin and collagen, which leads to the
AA development. One of the stages of MMPs activation
is associated with the increase of factor TGF-B (trans-
forming growth factor beta) and NFkB (nuclear factor
kappa beta). An important role in the LVA development
plays elastase and cathepsins, which damage the aortic
wall without the help of MMP. But elastase is activated
only when the level of cystatin C. Already at the aorta
to the diameter of 5 mm clearly observed lack of cysta-
tin C, which makes it an important marker of LVS’s
diagnostic. The first step in modern diagnostic of LVA
will become the screening of patients’ blood for detec-
tion MMP-2, MMP-9, OPG, cystatin C, TIMP-1, TIMP-
2, IL-6, TNF-a, TGF-B and NFkB. In case of a positive
result of serologic testing the presence of AA can be
considered. The second step will be instrumental meth-
ods. It will be the imaging of the aorta - MRI or CT
with contrast, which allows determining the localization
of the AA. The third step will include the results of his-
todiagnosis and immunomorphology of biopsy speci-
mens. This is algorithm will permit a detection of the
disease at the preclinical stage, which allow to start
timely pharmacoprevention. Findings research provide a
way for designing primary preclinical diagnostic proto-
cols for more adequate assessment of aortic wall status
and early implementation of preventive drug therapy.
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